Compare DBI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBI | ACIU |
|---|---|---|
| Founded | 1991 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.8M | 244.3M |
| IPO Year | 2005 | 2015 |
| Metric | DBI | ACIU |
|---|---|---|
| Price | $5.84 | $2.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.75 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 947.5K | 297.7K |
| Earning Date | 06-09-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 15.00 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,892,671,000.00 | N/A |
| Revenue This Year | $1.29 | $706.75 |
| Revenue Next Year | $1.88 | $321.13 |
| P/E Ratio | $291.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.55 | $1.94 |
| 52 Week High | $9.17 | $4.00 |
| Indicator | DBI | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 43.49 |
| Support Level | $3.30 | N/A |
| Resistance Level | $8.28 | $3.92 |
| Average True Range (ATR) | 0.41 | 0.14 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 11.03 | 43.51 |
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.